IL18 and Insulin resistance: The MD reduces insulin resistance, lowers systolic and diastolic blood pressure, and decreases levels of intercellular adhesion and vascular molecule-1, C-reactive protein, interleukin (IL)-6, and IL-18 (25), as well as UA levels (33), contributing to a decreased risk of CVDs.